NEURACAP
M&A UpdateUpdated · 7 pages · Free to read

Immunology and Inflammation Therapeutics M&A update, 14–28 September 2026

This bi-weekly update tracks share-price moves, major news catalysts and M&A activity across Immunology and Inflammation Therapeutics from September 14–28, 2026, for operators, acquirers and advisors monitoring sector positioning and deal flow.

For information only. Not an appraisal or a fairness opinion.

The deeper read: Immunology and Inflammation Therapeutics Sector Outlook — September 2026

Key figures

Sector median move
-5.0%
14 covered names, close-to-close
EV/Revenue median (CY2026E)
7.9x
Premium tier ≥10.2x; Discount tier <5.9x
Alvotech (ALVO) move
+21.8%
close-to-close
Arcutis Biotherapeutics (ARQT) move
+12.6%
close-to-close

Read the report

NeuraCap

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › IMMUNOLOGY AND INFLAMMATION THERAPEUTICS

Revenue Evidence Earns the Bid While Single-Asset Risk Gets Marked Down

This update covers what moved, what companies announced and what changed in the transaction record across Immunology and Inflammation Therapeutics from September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Immunology and Inflammation Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

1

1 / 7

Executive summary

Across the fourteen covered names, ten fell and the median move was -5.0%, against a +0.8% S&P 500 return, while Alvotech (ALVO, +21.8%) and Arcutis Biotherapeutics, Inc. (ARQT, +12.6%) carried the period's upside. The steepest declines concentrated in single-asset, clinical-stage names. One pending transaction — Aethlon Medical, Inc. and North Immunology, Inc. — joined the record with terms undisclosed. Our read: buyers paid for commercial visibility and stepped back from binary clinical exposure this period.

Key findings

  • 10 of 14 covered names fell; median move was -5.0%, sector-wide
  • ALVO (+21.8%) and ARQT (+12.6%) carried all of the period's upside
  • Clinical-stage single-asset names led declines: PALI -26.8%, ALMS -22.3%
  • One pending deal joined the record; enterprise value not yet disclosed

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01
    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › IMMUNOLOGY AND INFLAMMATION THERAPEUTICS

    Cover slide introducing the Immunology and Inflammation Therapeutics bi-weekly industry events and M&A update for September 14–28, 2026.

    This bi-weekly update covers what moved, what companies announced and what transacted across Immunology and Inflammation Therapeutics from September 14–28, 2026. We built it to answer four questions: what changed, who moved and most likely why, what transacted, and what it means for the people who act on it.

    Everything on this page

    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › IMMUNOLOGY AND INFLAMMATION THERAPEUTICS Revenue Evidence Earns the Bid While Single-Asset Risk Gets Marked Down This update covers what moved, what companies announced and what changed in the transaction record across Immunology and Inflammation Therapeutics from September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Immunology and Inflammation Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    THE BI-WEEKLY BOTTOM LINE

    Buyers of Risk Paid for Commercial Visibility and Stepped Back from Clinical-Stage

    Summarizes the two-week period's key facts: most covered names fell, two names carried the upside, and one pending transaction joined the record.

    Ten of the fourteen covered names fell this period, with a median move of -5.0% against a S&P 500 return of +0.8%, so the drawdown reads as sector-specific rather than market-wide. Alvotech (ALVO) and Arcutis Biotherapeutics, Inc. (ARQT) carried all of the period's upside, rising +21.8% and +12.6% respectively, while the steepest declines clustered in single-asset, clinical-stage names. The transaction record also grew by one pending deal with terms not yet disclosed. Taken together, the period rewards commercial visibility and marks down binary clinical exposure — so we read this as buyers paying for evidence, not promise.

    Everything on this page

    THE BI-WEEKLY BOTTOM LINE Buyers of Risk Paid for Commercial Visibility and Stepped Back from Clinical-Stage The two-week period in one page · 14 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Immunology and Inflammation Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 10 of 14 Covered Names Fell; The Median Move Was -5.0% The S&P 500 returned +0.8% over the same window. Our read is that the drawdown sat inside the sector rather than across the broad market. 2 Two Names Carried All of the Period's Upside Alvotech (ALVO) rose +21.8%, with its strongest session of +9.9% on Sep 18. Arcutis Biotherapeutics, Inc. (ARQT) added +12.6%, including an +11.2% single-day gain. 3 The Losses Clustered in Clinical-Stage, Single-Asset Exposure Palisade Bio, Inc. (PALI) fell -26.8%, Alumis Inc. (ALMS) -22.3%, Immunic, Inc. (IMUX) -15.3% and Abivax S.A. (ABVX) -14.7%. Each sits well below the -5.0% median for the covered set. 4 The Transaction Record Grew by One Pending Deal Aethlon Medical, Inc. and North Immunology, Inc. entered the record on Sep 17 as a pending transaction with no disclosed enterprise value. That sits alongside 11 transactions in the trailing record. +21.8% Best mover — Alvotech (ALVO) worst: PALI -26.8% · 4 up / 10 down of 14 covered -5.0% Sector median two-week return vs S&P 500 +0.8% 1 Transactions announced in the two-week period terms not fully disclosed 2 Company filings in the window 8-K events read for driver attribution

  3. 03
    PUBLIC MARKET MOVERS

    Visibility Got Rewarded; Binary Clinical Exposure Got Repriced

    Shows the bi-weekly share-price movers, highlighting which names rose on commercial visibility and which fell on clinical-stage risk.

    Against a materiality bar of 11.7% on a sector-relative basis, ALVO's +21.8% move and ARQT's +12.6% move stand out as the period's clearest outliers, each following appearances at a major healthcare conference. On the downside, Palisade Bio, Inc. (PALI), Alumis Inc. (ALMS), Immunic, Inc. (IMUX) and Abivax S.A. (ABVX) each fell well past the -5.0% sector median. We read this dispersion as evidence that the market is pricing commercial proof points differently from single-asset clinical risk, not as a uniform sector repricing. So what: names with revenue or near-term commercial catalysts held up; names dependent on a single clinical readout did not.

    Everything on this page

    PUBLIC MARKET MOVERS Visibility Got Rewarded; Binary Clinical Exposure Got Repriced Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -5.0% · S&P 500 +0.8% · materiality bar ±11.7% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Immunology and Inflammation Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -5.0% Palisade Bio, Inc. (PALI) -26.8% No notable in-window news was identified that clearly explains the move. At -26.8%, it ran far below the -5.0% median for the covered set. Small-cap developers between catalysts can travel a long way from the sector median in either direction. UNEXPLAINED Alumis Inc. (ALMS) -22.3% No notable in-window news was identified that clearly explains the move. At -22.3%, the decline was well below the -5.0% sector median. Single-asset, single-indication exposure remains the sharpest source of price swings in this sector. UNEXPLAINED Alvotech (ALVO) +21.8% Shares moved following Alvotech's Sep 15 presentation at the Morgan Stanley 24th Annual Global Healthcare Conference and a reported brokerage average target price of $8.50 on Sep 21. A Discount-tier name can re-rate quickly when the commercial story is already visible in the numbers. COMPANY-SPECIFIC Abivax S.A. (ABVX) -14.7% The move followed Abivax S.A.'s Sep 21 business update and first-half 2026 results, which named a new Chief Medical Officer and a Chief Technical Officer to advance commercial supply readiness. Its best session came Sep 28 at +6.4%. Building commercial supply leadership ahead of launch reads as preparation, and the market prices the wait. COMPANY-SPECIFIC

  4. 04
    MAJOR NEWS & INDUSTRY CATALYSTS

    Access Promises Are Being Tested in Court While Enrollment Clocks Keep Running

    Lists the two-week period's highest-impact news events, including an access-related court case, tied to the underlying filings and articles.

    This page tracks the events that moved the needle most this period, each one linked back to its source filing or article rather than to summary commentary. The lead story is an access-related court test running in parallel with active enrollment timelines, which we read as a signal that commercial and clinical clocks are not always aligned. Every 'why it matters' line here is a NeuraCap read tied to a recorded source, not a projection. So what: watch the access case for signal on how payer and legal risk can move faster than trial readouts.

    Everything on this page

    MAJOR NEWS & INDUSTRY CATALYSTS Access Promises Are Being Tested in Court While Enrollment Clocks Keep Running The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Immunology and Inflammation Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 14 · NEWS · Newsfile Corp ARS Pharmaceuticals faces a securities class action with an October 5, 2026 deadline The claim centres on what investors were told about a payer coverage date. In this sector, formulary position and time to first fill decide launch value, so the dispute lands on the industry's core economics. Access timing is a disclosure-sensitive variable, not a background detail, for any name approaching launch. Sep 14 · NEWS · Newsfile Corp A second firm notice reminds ARS Pharmaceuticals investors of the same October 5 deadline Multiple notices in a single window point to an active lead-plaintiff process rather than an isolated filing, which extends the period over which the matter stays in front of the market. Litigation overhang can sit on a Discount-tier valuation long after the underlying access question is settled. Sep 15 · 8-K · SEC EDGAR Coya Therapeutics (COYA) enrolls its 100th patient in the Phase 2/3 ALSTARS trial of COYA 302 Full enrollment of 120 patients is expected and topline data is anticipated in early Q2 2027. Enrollment pace is the clearest signal a clinical-stage developer can give between readouts. Operators who can show a trial filling on schedule shorten the distance to a registrational readout. Sep 15 · NEWS · PRNewsWire AbbVie's Allergan Aesthetics takes aging biology and exosome science to the 2026 Science of Skin Summit An R&D-led scientific programme from a Core-tier incumbent shows where a diversified owner is putting research attention alongside its established immunology footprint. Incumbents keep seeding adjacent science while their core franchises mature, which shapes the acquisition bid over time. Sep 15 · NEWS · Business Wire Investor notice covers ARS Pharmaceuticals losses above $100,000 from the March to June 2026 window The notices define a specific purchase window tied to the coverage timeline. That fixes the period the market will scrutinise as the case proceeds. A defined claim window gives the sector a concrete reference point for how coverage guidance is judged after the fact. Sep 15 · NEWS · GlobeNewsWire SBS Law opens the lead-plaintiff window in the ARS Pharmaceuticals securities case The procedural step keeps the matter live into the fourth quarter and adds a known calendar item for a name already carrying an access dispute. Known legal dates become part of how the market frames the next set of commercial updates.

  5. 05
    M&A & STRATEGIC ACTIVITY

    One Pending Transaction Joins the Record, with Terms Not Disclosed

    Reports the single new transaction added to the record this period, a pending deal between Aethlon Medical, Inc. and North Immunology, Inc., with terms undisclosed.

    One transaction entered the record this period: Aethlon Medical, Inc. and North Immunology, Inc., announced September 17 as pending, with no disclosed enterprise value. That adds to a trailing record of prior transactions, though the lack of disclosed terms means it does not yet move the pricing comparison set. We treat 'why the deal happened' as a NeuraCap read of the recorded evidence, not a confirmed rationale. So what: the reference set for deal pricing is effectively unchanged this period — watch for terms to be disclosed before drawing multiples from it.

    Everything on this page

    M&A & STRATEGIC ACTIVITY One Pending Transaction Joins the Record, with Terms Not Disclosed 1 transaction announced · September 14–28, 2026 · figures link to the filing Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Immunology and Inflammation Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 Sep 17 n/a Aethlon Medical, Inc. Aethlon Medical, Inc. moves on North Immunology, Inc. in a pending transaction EV / LTM revenue n/a EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The record shows the transaction as pending as of Sep 17 with no stated consideration. HOW THE TARGET WAS VALUED No enterprise value, EV/Revenue or EV/EBITDA is reported for this transaction, so no multiple can be read from it. The trailing record carries 11 transactions and no reported median EV/EBITDA.

  6. 06
    WHAT IT MEANS

    What This Two-Week Period Changes for Operators, Buyers and Advisors

    Translates the two-week period into implications for operators, acquirers and advisors.

    For operators, the period's message is that commercial proof points — patient starts, formulary position, prior-authorization approval rates — are what set the bid. For acquirers, the reference set gained one pending deal but no new pricing data, so the comparison set for valuation is unchanged. For advisors, the dominant theme is the separation of commercial visibility from binary clinical exposure, visible in the same -5.0% median decline against ALVO's +21.8% and ARQT's +12.6%. So what: each audience should treat this period as confirming, not challenging, the value of demonstrated commercial traction over pipeline promise alone.

    Everything on this page

    WHAT IT MEANS What This Two-Week Period Changes for Operators, Buyers and Advisors The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Immunology and Inflammation Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2026E) median 7.9x 16 companies in the study 3 valuation tiers Standing thesis: Immunology and Inflammation Therapeutics spans clinical-stage developers and adjacent commercial models FOR OWNERS & OPERATORS Commercial Proof Points Set the Bid The names that traded higher this period were those with a visible commercial story. The KPIs behind that are patient starts and refill persistence, formulary position and covered lives, prior-authorization approval rate and time to first fill FOR ACQUIRERS The Reference Set Gained One Pending Deal and No New Pricing Data Aethlon Medical, Inc. and North Immunology, Inc. add a pending transaction to a trailing record of 11, but with no disclosed enterprise value the comparison set for pricing is unchanged. FOR ADVISORS Lead with Access Economics and Evidence Quality The period's dominant theme is that the market separated commercial visibility from binary clinical exposure: 10 of 14 covered names fell; the median move was -5.0%, while ALVO rose +21.8% and ARQT +12.6%.

  7. 07
    SOURCES & METHODOLOGY

    Sources, Methodology and Important Notice

    Explains the sources, methodology and evidentiary standards behind this bi-weekly update.

    Every figure in this update links back to the record it was taken from — SEC filings, consensus estimates or market prices through September 28, 2026. Driver attributions use calibrated language because they represent NeuraCap's read of recorded evidence, not confirmed causation. This is the discipline that lets you trust the numbers on the preceding pages without re-checking each one. So what: use this page as the audit trail whenever a figure in the deck needs sourcing.

    Everything on this page

    SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Immunology and Inflammation Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 2 names below the floor were excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T180857Z_555_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: newsfilecorp.com · sec.gov · prnewswire.com · businesswire.com · globenewswire.com

Sources and methodology

This update covers Immunology and Inflammation Therapeutics over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 14 listed companies whose core business is Immunology and Inflammation Therapeutics under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: AbbVie Inc. (ABBV), Abivax S.A. (ABVX), Alumis Inc. (ALMS), Alvotech (ALVO), argenx SE (ARGX), Arcutis Biotherapeutics, Inc. (ARQT), Coya Therapeutics, Inc. (COYA), DBV Technologies S.A. (DBVT), Immunic, Inc. (IMUX), Kiniksa Pharmaceuticals International, plc (KNSA), Palisade Bio, Inc. (PALI), ARS Pharmaceuticals, Inc. (SPRY), Spyre Therapeutics, Inc. (SYRE), Vera Therapeutics, Inc. (VERA). 2 names below the floor were excluded from the statistics: ATYR, IMA.

Window and company universe

This update covers Immunology and Inflammation Therapeutics over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 14 listed companies whose core business is Immunology and Inflammation Therapeutics under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: AbbVie Inc. (ABBV), Abivax S.A. (ABVX), Alumis Inc. (ALMS), Alvotech (ALVO), argenx SE (ARGX), Arcutis Biotherapeutics, Inc. (ARQT), Coya Therapeutics, Inc. (COYA), DBV Technologies S.A. (DBVT), Immunic, Inc. (IMUX), Kiniksa Pharmaceuticals International, plc (KNSA), Palisade Bio, Inc. (PALI), ARS Pharmaceuticals, Inc. (SPRY), Spyre Therapeutics, Inc. (SYRE), Vera Therapeutics, Inc. (VERA). 2 names below the floor were excluded from the statistics: ATYR, IMA.

How the moves and statistics are computed

Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.

Events, news and how a move is attributed

Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.

Transactions in the window and the trailing record

Transactions are taken from SEC filings by announcement date; 1 was announced inside the window. The trailing record of 11 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.

Sources

Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.

Interpretation and important notice

'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Immunology and Inflammation Therapeutics?

Company valuation reports run the same method against a single business — public or private.